AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira knock-offs beyond 2020 suggests that investors ought to take a good, hard look at owning this company's stock in their portfolio.
As of the second quarter, Humira generates about two-thirds of AbbVie's $28 billion in annualized sales. Clearly, sidestepping the threat posed by expiring Humira patents won't be easy.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com